Trinity buys immunodiagnostics firm Fitzgerald:
This article was originally published in Clinica
Executive Summary
Nasdaq-listed Trinity Biotech (Bray, Ireland) has paid $16m in cash and shares to acquire Fitzgerald Industries International, a Concord, Massachusetts-based provider of immunodiagnostic products. Fitzgerald had revenues of $7m in 2003. It will continue to sell antibodies, antigens, proteins, enzymes and immunochemicals among other products as a stand-alone business in the Trinity group. According to Trinity CEO Ronan O'Caoimh, Fitzgerald's product sales will increase thanks to Trinity's marketing capabilities, and Trinity will be able to source raw materials at better prices in future.